Guselkumab is an interleukin-23 inhibitor indicated for treatment of moderate-to-severe plaque psoriasis.
Objective:
The objective was to determine the relative efficacy and safety of guselkumab compared to other biologics.
Methods:
A systematic review was performed to identify randomized controlled trials (RCTs). Bayesian network meta-analyses (NMAs) were conducted using meta-regression analyses that adjusted for cross-trial differences and risk differences. The primary outcome was Psoriasis Area and Severity Index (PASI) 90 response. Other efficacy and safety outcomes were considered. Several meta-regressions were performed to account for variations in patient and study characteristics: baseline risk adjustment (ie, control group response), prior biologic use, duration of psoriasis, weight, age, race, and baseline PASI/dermatology life quality index scores. The best-fitting model using predefined criteria was selected.
Results:
Forty-five RCTs were identified. Patient and study characteristics differed between RCTs as reflected in variations in control group response. Both the baseline risk-adjusted NMA and the risk-difference NMA fit the data best and suggested guselkumab has one of the highest PASI 90 responses. Pairwise comparisons from the baseline risk-adjusted PASI 90 NMA suggested guselkumab has comparable efficacy with ixekizumab (relative risk [RR]: 0.999, 95% credible intervals [CrIs]: 0.89-1.13) and brodalumab (RR: 1.04, 95% CrIs: 0.91-1.17) and superior efficacy versus all other treatments in the network (RR range, 1.20 to 43.22). Guselkumab was superior or comparable to other therapies for other efficacy outcomes and had a more favorable safety profile than most.
Conclusions:
Guselkumab has one of the highest PASI 90 responses among psoriasis treatments; similar findings were observed for other efficacy outcomes. Guselkumab has a favorable benefit–risk balance compared to moderate-to-severe psoriasis therapies.
Di MeglioPVillanovaFNestleFO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354.
3.
MrowietzUKragballeKReichK. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
4.
BlauveltAPappKAGriffithsCE. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2016;76(3):405–417.
5.
ReichKArmstrongAWFoleyP. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2016;76(3):418–431.
6.
CaldwellDMAdesAEHigginsJP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897–900.
7.
Catala-LopezFTobiasACameronCMoherDHuttonB. Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int. 2014;34(11):1489–1496.
8.
SalantiGHigginsJPAdesAEIoannidisJP. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008;17(3):279–301.
9.
Gomez-GarciaFEpsteinDIsla-TejeraBLorenteAVelez Garcia-NietoARuanoJ. Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. Br J Dermatol. 2017;176(3):594–603.
10.
GuptaAKDaigleDLyonsDC. Network meta-analysis of treatments for chronic plaque psoriasis in Canada. J Cutan Med Surg. 2014;18(6):371–378.
11.
HartzS. Network meta-analysis to evaluate the efficacy of ixekizumab in the treatment of moderate-to-severe psoriasis. Value in Health. 2016;19(7):A576.
Jabbar-LopezZKYiuZZNWardV. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol. 2017;137(8):1646–1654.
14.
NICE. Single technology appraisal. Apremilast for treating moderate to severe psoriasis [TA419]. 2016. https://www.nice.org.uk/guidance/ta419/history. Updated August, 2016. Accessed February, 2017.
15.
NICE. Single technology appraisal. Ixekizumab for treating moderate to severe plaque psoriasis [TA442]. 2016. https://www.nice.org.uk/guidance/ta442/historyUpdated November, 2016. Accessed February, 2017.
16.
NICE. Single technology appraisal. Secukinumab for the treatment of moderate to severe plaque psoriasis [TA350]. 2015. https://www.nice.org.uk/guidance/ta350/history. Updated May, 2015. Accessed February, 2017.
17.
SawyerLFotheringhamIWrightEYasmeenNGibbonsCHolmen MollerA. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. J Dermatolog Treat. 2018;29(6):557–568.
18.
SbidianEChaimaniAGarcia-DovalI. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD011535.
19.
SignorovitchJEBettsKAYanYS. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response. Br J Dermatol. 2015;172(2):504–512.
20.
DiasSSuttonAJAdesAEWeltonNJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–617.
21.
DiasSSuttonAJWeltonNJAdesAE. Evidence synthesis for decision making 3: heterogeneity—subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making. 2013;33(5):618–640.
22.
HoaglinDCHawkinsNJansenJP. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14(4):429–437.
23.
JansenJPFleurenceRDevineB. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417–428.
24.
CameronCDruchokCLaBrashL. Guselkumab for the treatment of moderate-to-severe plaque psoriasis: protocol for a systematic review and network meta-analysis. PROSPERO, 2017CRD42017060190. http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017060190. Updated March, 2017. Accessed April, 2017.
25.
HigginsJPAltmanDGGotzschePC. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
26.
DiasSWeltonNJSuttonAJAdesAE. Evidence synthesis for decision making 1: introduction. Med Decis Making. 2013;33(5):597–606.
27.
DiasSWeltonNJSuttonAJCaldwellDMLuGAdesAE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33(5):641–656.
28.
SalantiGAdesAEIoannidisJP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163–171.
29.
LunnDJThomasABestNSpiegelhalterD. WinBUGS—a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325–337.
30.
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013. http://www.R-project.org/. Accessed March, 2017.
31.
SpiegelhalterDBestNCarlinBVan Der LindeA. Bayesian measures of model complexity and fit. J R Stat Soc. 2002;64(4):583–639.
32.
HuttonBSalantiGCaldwellDM. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784.
33.
AsahinaANakagawaHEtohTOhtsukiM; Adalimumab M04-688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol. 2010;37(4):299–310.
34.
BachelezHvan De KerkhofPCStrohalR. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552–561.
35.
BlauveltAPrinzJCGottliebAB. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–493.
36.
CaiLGuJZhengJ. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017;31(1):89–95.
37.
de VriesAThioHde KortW. A prospective randomised controlled trial comparing infliximab and etanercept in patients with moderate to severe chronic plaque type psoriasis: the Psoriasis Infliximab versus Etanercept Comparison Evaluation, the PIECE study. Br J Dermatol. 2016;176(3):624–633.
38.
GordonKBBlauveltAPappKA. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356.
39.
GottliebABLeonardiCKerdelFMehlisSOldsMWilliamsDA. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):652–660.
40.
GriffithsCEReichKLebwohlM. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
41.
GriffithsCEStroberBEvan de KerkhofP. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–128.
42.
GriffithsCEThaciDGerdesS. The EGALITY study: a confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis. Br J Dermatol. 2016;176(4):928–938.
43.
IgarashiAKatoTKatoMSongMNakagawaH; Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39(3):242–252.
44.
LangleyRGElewskiBELebwohlM. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
45.
LebwohlMStroberBMenterA. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328.
46.
LeonardiCLKimballABPappKA. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).[Erratum appears in Lancet. 2008 May 31;371(9627):1838]. Lancet. 2008;371(9625):1665–1674.
47.
LeonardiCLPowersJLMathesonRT. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–2022.
48.
MenterAFeldmanSRWeinsteinGD. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e31–15.
49.
MenterATyringSKGordonK. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–115.
50.
MrowietzULeonardiCLGirolomoniG. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27–36.e21.
51.
PappKReichKLeonardiCL. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
52.
PappKALangleyRGLebwohlM. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684.
53.
PappKAReichKPaulC. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286.
54.
PappKATyringSLahfaM. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304–1312.
55.
PaulCCatherJGooderhamM. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–1399.
56.
PaulCLacourJPTedremetsL. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–1090.
57.
ReichKGooderhamMGreenL. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2016;31(3):507–517.
58.
ReichKNestleFOPappK. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–1374.
59.
SauratJHStinglGDubertretL. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–566.
60.
StroberBECrowleyJJYamauchiPSOldsMWilliamsDA. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):661–668.
61.
StrohalRPuigLChouelaE. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat. 2013;24(3):169–178.
62.
ThaciDBlauveltAReichK. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409.
63.
ToriiHNakagawaH, Japanese infliximab study investigators. infliximab monotherapy in japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. a randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59(1):40–49.
64.
TsaiTFHoJCSongM. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154–163.
65.
TyringSGottliebAPappK. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29–35.
66.
van de KerkhofPCSegaertSLahfaM. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol. 2008;159(5):1177–1185.
67.
YangHZWangKJinHZ. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J. 2012;125(11):1845–1851.
68.
ZhuXZhengMSongM. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol. 2013;12(2):166–174.
69.
ReichKPappKABlauveltA. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288.
70.
ReichKPinterALacourJP. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase 3 study. Br J Dermatol. 2017;177(4):1014–1023.
71.
PappKBachelezHCostanzoA. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76(6):1093–1102.
72.
BatsonSSuttonAAbramsK. Exploratory network meta regression analysis of stroke prevention in atrial fibrillation fails to identify any interactions with treatment effect. PloS One. 2016;11(8):e0161864.
MoherDLiberatiATetzlaffJAltmanDGGroupP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med. 2009;6(7):e1000097.
75.
LiberatiAAltmanDGTetzlaffJ. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Plos Med. 2009;6(7):e1000100.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
